AUTHOR=Bartolome Jorge , Molto Consolacion , Benitez-Fuentes Javier David , Fernandez-Hinojal Gonzalo , Manzano Aranzazu , Perez-Segura Pedro , Mittal Abhenil , Tamimi Faris , Amir Eitan , Ocana Alberto 

TITLE=Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis

JOURNAL=Frontiers in Immunology

VOLUME=Volume 14 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1165813

DOI=10.3389/fimmu.2023.1165813

ISSN=1664-3224

ABSTRACT=Identification of modulators of the immune response with inhibitory properties that could be susceptible for therapeutic intervention is a key goal in cancer research. An example is the human leukocyte antigen G (HLA-G), a nonclassical major histocompatibility complex (MHC) class I molecule, involved in cancer progression. In this article we performed a systematic review and meta-analysis on the association between HLA-G expression and outcome in solid tumors. A total of 25 studies met the inclusion criteria. These studies comprised data from 4871 patients reporting overall survival (OS), and 961 patients, reporting disease free survival (DFS). This study was performed in accordance with PRISMA guidelines and registered in PROSPERO. HLA-G expression was associated with worse OS (HR 2.09, 95% CI = 1.67 to 2.63; P < .001), that was higher in gastric (HR = 3.40; 95% CI = 1.64 to 7.03), pancreatic (HR = 1.72; 95% CI = 0.79 to 3.74) and colorectal (HR = 1.55; 95% CI = 1.16 to 2.07) cancer. No significant differences were observed between the most commonly utilized antibody (4H84) and other methods of detection. HLA-G expression was associated with DFS which approached but did not meet statistical significance. In summary, we describe the first meta-analysis associating HLA-G expression and worse survival in a variety of solid tumors.